Bausch + Lomb Corporation (BLCO) Fair Value 2026

BLCO · Medical Instruments & Supplies ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.3 /10

32 fundamental signals · 7 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-08-28, Bausch + Lomb Corporation (BLCO) trades at $17.15, versus a $25.64 median fair value across its 7 active models — 49.5% above the current price. QOC: 6.3/10. Value Trap Risk: 30/100 (LOW). 7/13 models active.

Key Facts

Ticker
BLCO
Price
$17.15
Quality Score
6.3/10
Value Trap Risk
30/100
Models Active
7/13
Last Updated
Strength: First Chicago suggests +162.3% upside with 61% confidence
Risk: Limited model coverage (7/13) may reduce confidence

Is Bausch + Lomb Corporation (BLCO) Undervalued or Overvalued in 2026?

According to CirclFi’s 7-model valuation engine, Bausch + Lomb Corporation (BLCO) appears undervalued as of : the median of 7 independent fair value estimates is $25.64, 49.5% above the current price of $17.15. Estimates range from $9.01 to $44.99. BLCO scores 6.3/10 on fundamental quality and 30/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. BLCO’s +49.5% gap is wider than that market norm, and the Medical Instruments & Supplies sector median is -29.3%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Bausch + Lomb Corporation Stock in 2026? →

What Fair Value Does Each Model Give BLCO?

7 Intrinsic Value Models vs. Current Price ($17.15)

Core Models (Unlocked)
Model Fair Value Upside
Ensemble · Low Conviction
 $25.19 +46.9%
Scenario · High Conviction
 $44.99 +162.3%
Intrinsic · High Conviction
 $9.01 -47.5%
Unlock the Full Matrix

Access 4 additional models including PWERM, Regime Cross-Sectional, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 7 Models →

Cancel anytime · No contracts · Instant access

What Is BLCO's Fair Value Range?

Spread across 7 independent models · $9.01 to $44.99

CirclFi's 7 active models place Bausch + Lomb Corporation (BLCO) between $9.01 and $44.99 per share, a spread of 140% of the median. The median of that range — $25.64 — is the fair value CirclFi publishes for BLCO, against a current price of $17.15.

Low · EROICHigh · First Chicago
$9.01median $25.64$44.99
Where the range comes from
Most bearish modelEROIC Spread$9.01
Most bullish modelFirst Chicago$44.99
Model agreement5 bullish · 2 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BLCO. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BLCO, not a CirclFi price target. How each model works →

What Is Bausch + Lomb Corporation (BLCO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Bausch + Lomb Corporation at $17.15. With an estimated intrinsic value of $25.64 and 5 of 7 models pointing higher, the median implied return is +49.5%. The most optimistic model, First Chicago, places fair value at $44.99 (+162.3%), while EROIC — the most conservative — estimates $9.01 (-47.5%). This +209.8% gap reflects genuine analytical uncertainty about Bausch + Lomb Corporation's intrinsic worth.

What Do the Models Say About BLCO?

7 of 13 models are currently active for BLCO. Of these, 5 models suggest upside while 2 models suggest overvaluation. Taken together, their median fair value for BLCO is $25.64 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does BLCO Rank in Medical Instruments & Supplies?

Among 56 Medical Instruments & Supplies stocks, BLCO ranks #33 by Quality of Company score. CirclFi's QOC score of 6.3/10 evaluates 32 fundamental signals. A score of 6.3 indicates above-average quality.

See all Most Undervalued Medical Instruments & Supplies Stocks →

Bausch + Lomb Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BLCO a Value Trap?

CirclFi's Value Trap algorithm assigns BLCO a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

7 of 13 models are active for Bausch + Lomb Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Bausch + Lomb Corporation scores 6.3 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +209.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BLCO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BLCO's 7 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bausch + Lomb Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Instruments & Supplies Stocks Should You Also Analyze?

11 related Medical Instruments & Supplies stocks with 13-model coverage

MMEDMiniMed Group, Inc.QOC 6.3TFXTeleflex IncorporatedQOC 6.2BAXBaxter International Inc.QOC 6.3RVPRetractable Technologies, Inc.QOC 6.2KRMDKORU Medical Systems, Inc.QOC 6.5MLSSMilestone Scientific Inc.QOC 6.2ZTEKZentek Ltd.QOC 5.4MMSIMerit Medical Systems, Inc.QOC 8.7WRBYWarby Parker Inc.QOC 7.6ISRGIntuitive Surgical, Inc.QOC 9.4RMDResMed Inc.QOC 9.4

Read investment analysis: MMED · TFX · BAX · RVP · KRMD · MLSS · ZTEK · MMSI · WRBY · ISRG · RMD

Which Other Stocks Have a Similar Quality Score to BLCO?

7 companies across all industries closest to BLCO’s Quality of Company score of 6.3/10.

SIFYSify Technologies LimitedQOC 6.3ALCOAlico, Inc.QOC 6.3AMPXAmprius Technologies, Inc.QOC 6.3IQiQIYI, Inc.QOC 6.3BGSB&G Foods, Inc.QOC 6.3ORMPOramed Pharmaceuticals Inc.QOC 6.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SIFY · ALCO · AMPX · IQ · BGS · ORMP · NVDA

Where Does BLCO Sit in CirclFi's Medical Instruments & Supplies Rankings?

BLCO is ranked against every other Medical Instruments & Supplies stock CirclFi covers in each of these screens.

See all Medical Instruments & Supplies stocks ranked →

What Else Do Investors Ask About Bausch + Lomb Corporation’s Valuation?

What is Bausch + Lomb Corporation's intrinsic value in 2026?

CirclFi puts Bausch + Lomb Corporation (BLCO)'s intrinsic value at $25.64 — the median of 7 independent model estimates as of 2026-08-28, ranging from $9.01 to $44.99. The Quality of Company score is 6.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BLCO overvalued or undervalued right now?

At $17.15, 5 of 7 active models suggest BLCO may be undervalued, while 2 indicate potential overvaluation. The median of all 7 fair value estimates is $25.64, 49.5% above the current price of $17.15 — a consensus view that BLCO is undervalued. The assessment depends on which methodology best fits Bausch + Lomb Corporation's business model in Medical Instruments & Supplies.

What does a Quality of Company score of 6.3 mean for BLCO?

Bausch + Lomb Corporation's QOC of 6.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BLCO?

CirclFi analyzes BLCO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 7 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BLCO?

Of the 7 models currently active on BLCO, First Chicago is the most bullish at $44.99 per share, and EROIC Spread is the most bearish at $9.01. CirclFi's published fair value for BLCO is the median of that range, $25.64, not either extreme. The gap between the two ends equals 140% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BLCO a value trap in 2026?

Bausch + Lomb Corporation's Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 7-model valuation engine, Bausch + Lomb Corporation (BLCO) has a median fair value of $25.64 — 49.5% above the current price of $17.15 — as of 2026-08-28.” Source: circlfi.com/stock/BLCO/ · Methodology
Primary sources for this BLCO valuation
  • Financial statements: Bausch + Lomb Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001860742) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BLCO as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 7 mathematical frameworks give you clarity on BLCO.

Unlock All 7 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

4 models hidden for BLCO Unlock All 7 — $39/mo